JP2011515458A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515458A5
JP2011515458A5 JP2011501337A JP2011501337A JP2011515458A5 JP 2011515458 A5 JP2011515458 A5 JP 2011515458A5 JP 2011501337 A JP2011501337 A JP 2011501337A JP 2011501337 A JP2011501337 A JP 2011501337A JP 2011515458 A5 JP2011515458 A5 JP 2011515458A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
protease inhibitor
composition according
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011501337A
Other languages
English (en)
Japanese (ja)
Other versions
JP5395160B2 (ja
JP2011515458A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2009/000223 external-priority patent/WO2009118722A2/en
Publication of JP2011515458A publication Critical patent/JP2011515458A/ja
Publication of JP2011515458A5 publication Critical patent/JP2011515458A5/ja
Application granted granted Critical
Publication of JP5395160B2 publication Critical patent/JP5395160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011501337A 2008-03-26 2009-02-26 タンパク質の経口投与方法及び組成物 Active JP5395160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6477908P 2008-03-26 2008-03-26
US61/064,779 2008-03-26
PCT/IL2009/000223 WO2009118722A2 (en) 2008-03-26 2009-02-26 Methods and compositions for oral administration of proteins

Publications (3)

Publication Number Publication Date
JP2011515458A JP2011515458A (ja) 2011-05-19
JP2011515458A5 true JP2011515458A5 (cg-RX-API-DMAC7.html) 2012-04-05
JP5395160B2 JP5395160B2 (ja) 2014-01-22

Family

ID=41114402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501337A Active JP5395160B2 (ja) 2008-03-26 2009-02-26 タンパク質の経口投与方法及び組成物

Country Status (10)

Country Link
US (3) US10058593B2 (cg-RX-API-DMAC7.html)
EP (2) EP3777831B1 (cg-RX-API-DMAC7.html)
JP (1) JP5395160B2 (cg-RX-API-DMAC7.html)
CN (1) CN102037121B (cg-RX-API-DMAC7.html)
AU (1) AU2009230718B2 (cg-RX-API-DMAC7.html)
CA (3) CA2719272C (cg-RX-API-DMAC7.html)
NZ (1) NZ588603A (cg-RX-API-DMAC7.html)
RU (1) RU2504373C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009118722A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007522B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722054B1 (en) * 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
RU2504373C2 (ru) 2008-03-26 2014-01-20 ОРАМЕД Лтд. Способы и композиции для перорального введения протеинов
CA2723434C (en) * 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
MX346316B (es) * 2010-02-25 2017-03-15 Evonik Roehm Gmbh Formulacion farmaceutica o nutraceutica.
BR112013000452A2 (pt) 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
WO2013102899A1 (en) 2012-01-03 2013-07-11 Oramed Ltd. Methods and compositions for treating diabetes
ES2912138T3 (es) * 2012-02-01 2022-05-24 Oramed Ltd Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
EP3003267A1 (en) * 2013-05-30 2016-04-13 Novo Nordisk A/S Novel oral pharmaceutical composition for treatment of diabetes
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
CN104922682A (zh) * 2014-03-20 2015-09-23 中国科学院大连化学物理研究所 一种胰蛋白酶抑制剂及其应用
WO2015176031A2 (en) 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN113230386B (zh) * 2021-03-07 2022-04-12 合肥天汇孵化科技有限公司 胸腺法新组合物及其用途
US20240366731A1 (en) * 2021-08-12 2024-11-07 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
EP4400094A4 (en) * 2021-09-07 2025-08-27 D&D Pharmatech Inc PHARMACEUTICAL COMPOSITION COMPRISING A PHYSIOLOGICALLY ACTIVE SUBSTANCE AND AN EXCIPIENT
WO2025147459A1 (en) * 2024-01-04 2025-07-10 Nano Precision Medical, Inc. Stabilization of peptides and proteins in implantable devices and formulations
US12466883B1 (en) 2024-05-13 2025-11-11 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
EP0351651B1 (en) 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE69740096D1 (de) * 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000050793A (ja) 1998-08-07 2000-02-22 Meiji Milk Prod Co Ltd 人工乳組成物
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CZ305123B6 (cs) 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) * 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
CN1741805A (zh) 2001-07-18 2006-03-01 索莱有限责任公司 高蛋白质鲍曼－比尔克抑制剂浓缩物及其生产方法
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
CN101027318B (zh) * 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) * 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
WO2008142482A2 (en) 2006-11-01 2008-11-27 Pronova Biopharma Norge As Omega-3 lipid compounds
PL2144618T5 (pl) 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bio-skuteczne kompozycje oleju z kryla
RU2504373C2 (ru) 2008-03-26 2014-01-20 ОРАМЕД Лтд. Способы и композиции для перорального введения протеинов
CA2723434C (en) 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JPWO2009151125A1 (ja) 2008-06-13 2011-11-17 持田製薬株式会社 肝障害の診断及び治療
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
US20090312302A1 (en) 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
KR101783817B1 (ko) 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
CN103988973A (zh) 2009-12-30 2014-08-20 索莱有限责任公司 大豆乳清蛋白组合物及其回收方法
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
CA2804506C (en) 2010-07-06 2018-08-21 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
WO2013102899A1 (en) 2012-01-03 2013-07-11 Oramed Ltd. Methods and compositions for treating diabetes
ES2912138T3 (es) 2012-02-01 2022-05-24 Oramed Ltd Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
IL241462A0 (en) * 2015-09-10 2015-11-30 Yeda Res & Dev Heterologous engineering of betalain pigments in plants

Similar Documents

Publication Publication Date Title
CA3083198A1 (en) Methods and compositions for oral administration of proteins
JP2012500254A5 (cg-RX-API-DMAC7.html)
AU2020203101B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
Bao et al. Catfish hepcidin gene is expressed in a wide range of tissues and exhibits tissue-specific upregulation after bacterial infection
RU2010146372A (ru) Композиции и способы перорального введения эксенатида
AU2009283821B2 (en) Methods and compositions for oral administration of proteins
FI2571517T4 (fi) Insuliinien pitkävaikutteisia formulaatioita
US20100093636A1 (en) Methods of treating inflammation
JP2015524419A5 (cg-RX-API-DMAC7.html)
KR20170026635A (ko) 장기 재생을 위한 내인성 회장 브레이크 호르몬 경로의 활성화 및 관련 조성물, 치료 방법, 진단법, 및 조절 시스템
JP2016513712A5 (cg-RX-API-DMAC7.html)
JP2011501959A5 (cg-RX-API-DMAC7.html)
WO2011134284A1 (zh) 胰高血糖素样肽-1类似物及其应用
CN103429236A (zh) 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
HRP20160416T1 (hr) Kapsula za prevenciju kardiovaskularnih bolesti
JP2001526656A (ja) アミリンまたはアミリン・アゴニストを用いる胃炎を予防する方法
Wei et al. Intermittent protein restriction protects islet β cells and improves glucose homeostasis in diabetic mice
AU2017298648A1 (en) 1-methylnicotinamide for the treatment of diseases associated with C-reactive protein
Roa et al. Trefoil factor 3 (TFF3) expression is regulated by insulin and glucose
Wei et al. Mechanisms of sodium-glucose cotransporter 2 inhibitors in heart failure
Umezawa et al. Sodium-glucose co-transporter 2 inhibitors: prospects for canine myxomatous mitral valve disease and finding the “right drug” and the “right dose” for dogs
Lim et al. Butyrate and propionate, short chain fatty acids, attenuate myocardial damages by inhibition of apoptosis in a rat model of ischemia-reperfusion
CN103966243B (zh) 一种dna分子及其在制备糖尿病鼠模型中的应用
Wapnick et al. Changes in glucose tolerance and serum insulin following partial gastrectomy and intestinal resection
WO2012016419A1 (zh) Glp-1衍生物及其应用